AVTX- Avalo Therapeutics, Inc.

Insider activity in AVTX over the last quarter tilts toward selling: insiders offloaded a net 101,317 shares worth roughly $2.0M.

Classified under Biotechnology (Health Care sector), AVTX's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Neil Garry Arthur	190.3K	-	-
Other	Boyd Taylor	95.0K	-	-
Other	Doyle Mittie	51.8K	$1.04M	-
CFO	Sullivan Christopher Ryan	39.9K	$651.7K	-
Other	Riley Jennifer	37.0K	$725.6K	-

Buys and sells only

10 filings · page 9

Date	Insider	Role	Type	Shares	Price	Value	Chg%
Feb 3, 2020	Armistice Capital, LLC56	Director, 10% Owner	Buy	1,256,282	$3.98	$5,000,002.36	-216.1%
Dec 10, 2019	Calias Pericles	Chief Scientific Officer	Buy	2,913	$2.85	$8,294.77	+5.9%
Dec 10, 2019	Harrell James Archie Jr	Chief Commercial Officer	Buy	3,064	$2.85	$8,724.74	+35.8%
Dec 10, 2019	Miller Joseph M50	Chief Financial Officer	Buy	2,598	$2.85	$7,397.81	+5.6%
Sep 6, 2019	Armistice Capital, LLC56	Director, 10% Owner	Buy	2,200,000	$3.05	$6,706,000.00	+11.9%
Aug 30, 2019	Armistice Capital, LLC56	Director, 10% Owner	Buy	41,764	$3.22	$134,554.26	+0.2%
Aug 27, 2019	Pedder Simon	Executive Chairman Of The Bd	Buy	6,734	$2.98	$20,100.32	+2.6%
Aug 19, 2019	Armistice Capital, LLC56	Director, 10% Owner	Buy	12,184	$3.46	$42,189.23	-
Aug 14, 2019	Armistice Capital, LLC56	Director, 10% Owner	Buy	100,000	$3.33	$332,581.94	+33.3%
Jun 10, 2019	Phillips Matthew V	Chief Commercial Officer	Buy	523	$2.85	$1,489.24	+105.2%